vs
Side-by-side financial comparison of ASGN Inc (ASGN) and APTARGROUP, INC. (ATR). Click either name above to swap in a different company.
ASGN Inc is the larger business by last-quarter revenue ($970.0M vs $962.7M, roughly 1.0× APTARGROUP, INC.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 0.6%, a 7.2% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs -3.0%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $9.1M). Over the past eight quarters, APTARGROUP, INC.'s revenue compounded faster (2.6% CAGR vs -3.2%).
ASGN Inc is a leading U.S.-headquartered professional services and workforce solutions provider. It specializes in supplying skilled talent and consulting services across high-growth segments including information technology, creative, digital, life sciences, and engineering, primarily serving enterprise clients across North America.
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
ASGN vs ATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $970.0M | $962.7M |
| Net Profit | $5.5M | $74.3M |
| Gross Margin | 27.5% | — |
| Operating Margin | 2.9% | 11.0% |
| Net Margin | 0.6% | 7.7% |
| Revenue YoY | -3.0% | 13.5% |
| Net Profit YoY | -73.7% | -26.4% |
| EPS (diluted) | $0.13 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $970.0M | — | ||
| Q4 25 | $980.1M | $962.7M | ||
| Q3 25 | $1.0B | $961.1M | ||
| Q2 25 | $1.0B | $966.0M | ||
| Q1 25 | $968.3M | $887.3M | ||
| Q4 24 | $985.0M | $848.1M | ||
| Q3 24 | $1.0B | $909.3M | ||
| Q2 24 | $1.0B | $910.1M |
| Q1 26 | $5.5M | — | ||
| Q4 25 | $25.2M | $74.3M | ||
| Q3 25 | $38.1M | $127.9M | ||
| Q2 25 | $29.3M | $111.7M | ||
| Q1 25 | $20.9M | $78.8M | ||
| Q4 24 | $42.4M | $100.9M | ||
| Q3 24 | $47.5M | $100.0M | ||
| Q2 24 | $47.2M | $90.5M |
| Q1 26 | 27.5% | — | ||
| Q4 25 | 28.9% | — | ||
| Q3 25 | 29.4% | — | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 29.0% | — | ||
| Q3 24 | 29.1% | — | ||
| Q2 24 | 29.1% | — |
| Q1 26 | 2.9% | — | ||
| Q4 25 | 5.7% | 11.0% | ||
| Q3 25 | 6.7% | 14.2% | ||
| Q2 25 | 5.8% | 14.9% | ||
| Q1 25 | 4.8% | 12.8% | ||
| Q4 24 | 7.5% | 14.2% | ||
| Q3 24 | 7.7% | 15.2% | ||
| Q2 24 | 7.8% | 13.8% |
| Q1 26 | 0.6% | — | ||
| Q4 25 | 2.6% | 7.7% | ||
| Q3 25 | 3.8% | 13.3% | ||
| Q2 25 | 2.9% | 11.6% | ||
| Q1 25 | 2.2% | 8.9% | ||
| Q4 24 | 4.3% | 11.9% | ||
| Q3 24 | 4.6% | 11.0% | ||
| Q2 24 | 4.6% | 9.9% |
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.58 | $1.13 | ||
| Q3 25 | $0.87 | $1.92 | ||
| Q2 25 | $0.67 | $1.67 | ||
| Q1 25 | $0.48 | $1.17 | ||
| Q4 24 | $0.94 | $1.48 | ||
| Q3 24 | $1.06 | $1.48 | ||
| Q2 24 | $1.02 | $1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $143.6M | $409.5M |
| Total DebtLower is stronger | $1.5B | $1.1B |
| Stockholders' EquityBook value | $1.8B | $2.7B |
| Total Assets | $4.0B | $5.3B |
| Debt / EquityLower = less leverage | 0.82× | 0.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $143.6M | — | ||
| Q4 25 | $161.2M | $409.5M | ||
| Q3 25 | — | $264.8M | ||
| Q2 25 | — | $169.8M | ||
| Q1 25 | — | $136.8M | ||
| Q4 24 | $205.2M | $226.2M | ||
| Q3 24 | — | $327.9M | ||
| Q2 24 | — | $223.9M |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.2B | $546.0M | ||
| Q2 25 | $1.2B | $535.1M | ||
| Q1 25 | $1.3B | $561.2M | ||
| Q4 24 | $1.0B | $688.1M | ||
| Q3 24 | $1.0B | $822.7M | ||
| Q2 24 | $1.0B | $681.5M |
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $2.7B | ||
| Q3 25 | $1.8B | $2.8B | ||
| Q2 25 | $1.8B | $2.7B | ||
| Q1 25 | $1.8B | $2.5B | ||
| Q4 24 | $1.8B | $2.5B | ||
| Q3 24 | $1.8B | $2.5B | ||
| Q2 24 | $1.8B | $2.4B |
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $5.3B | ||
| Q3 25 | $3.7B | $5.1B | ||
| Q2 25 | $3.7B | $4.9B | ||
| Q1 25 | $3.7B | $4.5B | ||
| Q4 24 | $3.4B | $4.4B | ||
| Q3 24 | $3.4B | $4.6B | ||
| Q2 24 | $3.5B | $4.5B |
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.65× | 0.43× | ||
| Q3 25 | 0.64× | 0.20× | ||
| Q2 25 | 0.66× | 0.20× | ||
| Q1 25 | 0.72× | 0.22× | ||
| Q4 24 | 0.58× | 0.28× | ||
| Q3 24 | 0.58× | 0.32× | ||
| Q2 24 | 0.57× | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.7M |
| Free Cash FlowOCF − Capex | $9.1M | $96.9M |
| FCF MarginFCF / Revenue | 0.9% | 10.1% |
| Capex IntensityCapex / Revenue | 1.0% | 9.0% |
| Cash ConversionOCF / Net Profit | — | 2.47× |
| TTM Free Cash FlowTrailing 4 quarters | $290.6M | $299.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $102.3M | $183.7M | ||
| Q3 25 | $83.9M | $177.6M | ||
| Q2 25 | $124.9M | $126.0M | ||
| Q1 25 | $16.8M | $82.7M | ||
| Q4 24 | $100.2M | $178.2M | ||
| Q3 24 | $135.8M | $229.3M | ||
| Q2 24 | $90.7M | $143.6M |
| Q1 26 | $9.1M | — | ||
| Q4 25 | $93.7M | $96.9M | ||
| Q3 25 | $72.0M | $114.3M | ||
| Q2 25 | $115.8M | $62.5M | ||
| Q1 25 | $6.6M | $25.9M | ||
| Q4 24 | $88.9M | $112.2M | ||
| Q3 24 | $127.9M | $162.7M | ||
| Q2 24 | $85.4M | $75.4M |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.6% | 10.1% | ||
| Q3 25 | 7.1% | 11.9% | ||
| Q2 25 | 11.3% | 6.5% | ||
| Q1 25 | 0.7% | 2.9% | ||
| Q4 24 | 9.0% | 13.2% | ||
| Q3 24 | 12.4% | 17.9% | ||
| Q2 24 | 8.3% | 8.3% |
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 9.0% | ||
| Q3 25 | 1.2% | 6.6% | ||
| Q2 25 | 0.9% | 6.6% | ||
| Q1 25 | 1.1% | 6.4% | ||
| Q4 24 | 1.1% | 7.8% | ||
| Q3 24 | 0.8% | 7.3% | ||
| Q2 24 | 0.5% | 7.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 2.47× | ||
| Q3 25 | 2.20× | 1.39× | ||
| Q2 25 | 4.26× | 1.13× | ||
| Q1 25 | 0.80× | 1.05× | ||
| Q4 24 | 2.36× | 1.77× | ||
| Q3 24 | 2.86× | 2.29× | ||
| Q2 24 | 1.92× | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASGN
Segment breakdown not available.
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
